Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis

Involvement of CCL2/CCR2 macrophage recruitment in amodiaquine-induced liver injury

(2019) Alastair Mak et al.   Journal of Immunotoxicology

Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients

(2019) J. Rogado et al.   EUROPEAN JOURNAL OF CANCER

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms

(2019) Petros Fessas et al.   IMMUNOLOGY

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Peter Schmid et al.   LANCET ONCOLOGY

Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis

(2018) Oliver Krenkel et al.   HEPATOLOGY

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors

(2018) Eleonora De Martin et al.   JOURNAL OF HEPATOLOGY

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study

(2018) Taku Fujimura et al.   Oncotarget

Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).

(2018) Mariona Riudavets et al.   JOURNAL OF CLINICAL ONCOLOGY

Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study

(2018) Naoto Okada et al.   CLINICAL THERAPEUTICS

CD14+CD15−HLA-DR−myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure

(2017) Christine Bernsmeier et al.   GUT

MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure

(2017) Evangelos Triantafyllou et al.   GUT

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

(2017) Hans J. Hammers et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase

(2016) Nikhil Vergis et al.   GUT

Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury

(2016) Jana C. Mossanen et al.   HEPATOLOGY

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

(2016) Paul T. Nghiem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis

(2015) D. M. Foureau et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Treatment of PD-1−/−mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients

(2015) Imir G. Metushi et al.   HEPATOLOGY

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study

(2013) E. S. Andersen et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

The who's who of T-cell differentiation: Human memory T-cell subsets

(2013) Yolanda D. Mahnke et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

EBI2 Is a Negative Regulator of Type I Interferons in Plasmacytoid and Myeloid Dendritic Cells

(2013) Eugene Y. Chiang et al.   PLoS One

Increased CD163 expression is associated with acute-on-chronic hepatitis B liver failure

(2013) Hong Ye   WORLD JOURNAL OF GASTROENTEROLOGY

Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans

(2012) Charalambos Gustav Antoniades et al.   HEPATOLOGY

The three human monocyte subsets: implications for health and disease

(2012) Kok Loon Wong et al.   IMMUNOLOGIC RESEARCH

Cd81 Interacts with the T Cell Receptor to Suppress Signaling

(2012) Safak Isil Cevik et al.   PLoS One

Functional heterogeneity of human effector CD8+ T cells

(2011) H. Takata et al.   BLOOD

Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets

(2011) K. L. Wong et al.   BLOOD

Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions

(2011) N. Joller et al.   JOURNAL OF IMMUNOLOGY

Soluble CD163, a Novel Marker of Activated Macrophages, Is Elevated and Associated With Noncalcified Coronary Plaque in HIV-Infected Patients

(2011) Tricia H. Burdo et al.   JOURNAL OF INFECTIOUS DISEASES

Cloning, eukaryotic expression of human ISG20 and preliminary study on the effect of its anti-HBV

(2010) Youhua Hao et al.   Journal of Huazhong University of Science and Technology-Medical Sciences

Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade

(2010) Jeffrey Weber   SEMINARS IN ONCOLOGY

Hepatic recruitment of the inflammatory Gr1+monocyte subset upon liver injury promotes hepatic fibrosis

(2009) Karlin Raja Karlmark et al.   HEPATOLOGY

Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function

(2009) Mario-Ernesto Cruz-Munoz et al.   NATURE IMMUNOLOGY